Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial

UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer

“…The incidence of delayed diarrhoea, neurotoxicity, leucocytopenia and thrombocytopenia was more frequent in the IROX arm compared to the FOLFIRI arm [19] . Differences in the frequency of adverse events might therefore partly influence the present analysis.…”

“…This retrospective analysis included a subgroup of 105 patients with mCRC who were treated with an irinotecanbased chemotherapy within a large prospective randomized multicenter phase Ⅲ study which investigated the role of a low-dose irinotecan-based chemotherapy in patients with metastatic or advanced colorectal cancer (FIREtrial) [19] . Patients underwent UGT1A1 genotyping in order to evaluate UGT1A1 as a predictor for drug efficacy and/or toxicity for patients with low-dose irinotecan-based chemotherapy and to provide a future tool for a patient tailored chemotherapy.…”

Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer

“…The randomized N9741 phase III trial demonstrated clinical activity of IROX in the first-line setting is comparable with IFL [20•]. Similarly, a preliminary report of the first-line FIRE trial comparing FOLFIRI with IROX suggested similar efficacy between the regimens (objective RR = 46% vs 50%; median OS = 21.1 vs 18.6 months, respectively) [32]. The utility of second-line IROX was evaluated in a phase II trial of 62 patients with 5-FU-refractory disease randomized to IROX or a regimen of 5-FU/LV plus alternating irinotecan and oxaliplatin (FC/FO) [33].…”

ASCO-Update 2005 - Neuigkeiten vom 41. Meeting der American Society of Clinical Oncology/ASCO 2005

“…Die Ergebnisse der deutschen FIRE-Studie zum Vergleich von Irinotecan plus Oxaliplatin (IROX) oder infusionalem 5-FU plus Irinotecan zeigten keinen signifikanten Unterschied in der Wirksamkeit (PFS von 8,2 Monaten versus 7,0 Monaten; p = 0,17) und im Gesamtüberleben (21,9 Monate versus 19,3 Monate; p = 0,427). Auch bezüglich der Toxizität ergaben sich keine signifikanten Unterschiede zwischen beiden Protokollen [41].…”